Figures
- FIGURE 1
Reduction from baseline to 48 weeks in a) maintenance oral corticosteroid (mOCS) dose (p=0.0018), b) Birmingham Vasculitis Activity Score (BVAS) (p=0.0007) and c) Asthma Control Questionnaire score (ACQ) (p=0.012). Data are presented as a) median (interquartile range) and b and c) mean±sd.
Vol 6 Issue 4
Table of Contents
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
